Psychedelic therapy is increasingly becoming a part of clinical decision making, as evidenced by Compass Pathways’ announcement earlier this year of successful trial results for COMP360 psilocybin for treatment-resistant depression. Kimberly Chew, Senior Counsel, Husch Blackwell LLP, and L. Alison McInnes, MD, MS, Director of Psychedelic Medicine, Mindful Health Solutions, discuss the clinical realities and legal gray zones of psychedelic therapies as they move from controlled trials into real-world practice. They cover recent developments, the gap between clinical trials and clinical practice, Risk Evaluation and Mitigation Strategies, and what good early adoption looks like in the clinical setting. Kimberly and Alison authored a Health Law Weekly article on this topic.
View on YouTube or on the podcast site.